Clin2
NCT07724340Possibly a fitRecruiting

Study of AT673 plus semaglutide for type 2 diabetes and weight loss

Adults With Overweight/Obesity and Type 2 Diabetes

Part of Hormones & metabolism clinical trials.

This study tests a new medication called AT673 combined with semaglutide (Wegovy) to help people with type 2 diabetes and overweight or obesity lose weight and improve blood sugar. It is for people who have tried diet and exercise to lose weight but haven't had success.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
150 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older with type 2 diabetes.
  • Your BMI is 27 or higher (overweight or obese).
  • Your blood sugar control (HbA1c) is between 7% and 10%.
  • You have had diabetes for at least 6 months.
  • You are not taking insulin or certain other diabetes medications (like Ozempic or Mounjaro) in the past 6 months.
  • You have not had weight loss surgery in the past year.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06499857Recruiting· Phase 3
Semaglutide for atrial fibrillation and weight loss

This study tests whether a weekly injection of semaglutide (the same drug in Wegovy and Ozempic) can help people with atrial fibrillation lose weight and improve their heart condition. It's for people with AF who also have obesity, and may or may not plan to have a heart procedure called catheter ablation.

Phoenix, Arizona
NCT07400107Not yet recruiting· Phase 3
Weight loss study for people with type 2 diabetes

This study tests a new medicine called NNC0487-0111 to see how well it helps people with excess body weight and type 2 diabetes lose weight, compared to another medicine called semaglutide. It may be an option if you have type 2 diabetes and are looking to manage your weight.

Hollywood, Florida
NCT06633783Not yet recruiting· Phase 3
Semaglutide injection for weight loss study

This study tests an injectable medication called semaglutide to help with weight loss in people with a BMI of 28 or higher who have struggled to lose weight before. It compares the study drug to a similar approved weight loss medicine (Wegovy).

Xuancheng, Anhui
NCT07430059Not yet recruiting· Phase 1
Study of a Semaglutide Implant for Weight Management

This study tests a small implant placed under the skin that slowly releases semaglutide, a medication that helps with weight management. It's for people who are overweight but do not have diabetes.

NCT06909006Not yet recruiting· Phase 3
Semaglutide for type 1 diabetes with higher body weight

This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.

Hillerød, Denmark
NCT07627074Recruiting
Real-world weight loss study with semaglutide

This study tracks how semaglutide (an injectable medication that reduces appetite) helps adults lose weight in everyday life. Researchers want to understand how well it works and how safe it is for people starting the treatment.

Seattle, Washington

Hear when a new Adults With Overweight/Obesity and Type 2 Diabetes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.